Kyoto, Japan

Ryuichiro Nagamatsu

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Arkray, Inc.. Active years: 2017.


% Patents Active = 100.0

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ryuichiro Nagamatsu: Innovator in Urine Analysis Technology

Introduction

Ryuichiro Nagamatsu is a notable inventor based in Kyoto, Japan. He has made significant contributions to the field of medical diagnostics, particularly in the evaluation of urine samples. His innovative approach has the potential to enhance the understanding of kidney-related conditions.

Latest Patents

Nagamatsu holds a patent for a "Method for evaluating urine sample, analyzer, and analysis system." This method provides a way to obtain information about proteinuria and/or nephropathy from urine samples. It involves detecting proteins in the urine using two types of detection reagents that differ in their reactivity to at least one urinary protein. The results from these detections are used to calculate an indicator that aids in the evaluation of the urine sample.

Career Highlights

Ryuichiro Nagamatsu is associated with Arkray, Inc., a company known for its advancements in medical technology. His work focuses on improving diagnostic methods that can lead to better patient outcomes. With a patent portfolio that includes 1 patent, he continues to push the boundaries of innovation in his field.

Collaborations

Nagamatsu has collaborated with notable colleagues such as Shinya Nakajima and Hideko Kosaka. Their combined expertise contributes to the development of cutting-edge technologies in urine analysis.

Conclusion

Ryuichiro Nagamatsu's contributions to urine analysis technology exemplify the impact of innovation in medical diagnostics. His work not only enhances the understanding of kidney health but also paves the way for future advancements in the field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…